Key result
Beta-blockers linked to ~28% lower all-cause mortality in systolic HF patients excluded from MERIT-HF.
Why the study?
Beta-blockers improve prognosis in chronic systolic heart failure patients, but many clinical patients do not meet trial inclusion criteria such as those of MERIT-HF.
Does beta-blocker treatment reduce all-cause mortality in patients with chronic systolic heart failure who meet exclusion criteria for the MERIT-HF trial?
Population
675 patients with chronic systolic heart failure from the Ludwigshafen Heart Failure Registry
Comparison
Beta-blocker treatment vs no beta-blocker treatment
Design
Observational cohort study dividing patients by MERIT-HF inclusion criteria
Follow-up
Median 31.3 months
Authors
Loading...
Beta-blocker use was associated with lower mortality in non-trial HF patients; leaves open extension of RCT benefits to broader populations.
Cohort (n=675)
Does beta-blocker treatment reduce all-cause mortality in patients with chronic systolic heart failure who meet exclusion criteria for the MERIT-HF trial?
Hazard Ratio: 0.72 (95% CI 0.53–0.97)
Beta-blocker therapy is associated with significantly reduced long-term mortality in patients with chronic systolic heart failure, even among those with comorbidities or characteristics that would have excluded them from landmark randomized trials like MERIT-HF.
Jost et al. (2005) conducted a cohort in chronic systolic heart failure (n=675). Beta-blocker treatment vs. No beta-blocker treatment was evaluated on All-cause mortality (HR 0.72, 95% CI 0.53-0.97). Beta-blocker treatment significantly reduced all-cause mortality in chronic systolic heart failure patients meeting one or more exclusion criteria of the MERIT-HF trial (adjusted HR 0.72; 95% CI 0.53-0.97).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: